Rhode Island and Massachusetts Drunk Driving Auto Accident: Drive Sober or Get Pulled Over

August 21st, 2019

Did you know that approximately 696,900 people will be affected by a drunk driving accident just in Rhode Island? According to the Rhode Island Department of Traffic, there were 59 drunk driving fatalities just last year in 2018. The National Traffic Safety Administration will be launching their annual “Drive Sober or Get Pulled Over” campaign […]

Diabetes Drug Found to Increase Risk of Bladder Cancer

April 25th, 2014

On April 7, 2014, a federal jury in Louisiana revealed that Takeda did not sufficiently warn about bladder cancer risks of using Actos (pioglitazone). Reports suggest that Takeda performed experiments on animals before the drug went to market in 1999, and found an increased risk of bladder cancer when the animals were provided the drug. […]

Central Falls Attorney: Lawsuits Pour In Due To Dangerous Antipsychotic Drug

February 14th, 2014

The Department of Justice has been inspecting an antipsychotic drug called Risperdal since 2012. The drug is mainly used to treat schizophrenia, bipolar disorder, and irritability in people with autism. Over the years, many individual claims have been filed due to the development of gynecomastia and weight gains. The Food and Drug Administration approved Risperdal […]

RI Personal Injury Lawyer Case Digest: Mutual Pharm. Co. v. Bartlett Part II

November 29th, 2013

In Part I I told the story of Ms. Bartlett who suffered severe disfiguring injuries from taking a generic medication that did not include a warning about the possibility of suffering those injuries. She prevailed in the lower courts, but was then denied recovery by the Supreme Court of the United States in Mut. Pharm. […]

RI Personal Injury Lawyer Case Digest: Mutual Pharm. Co. v. Bartlett Part I

November 27th, 2013

In the recent Supreme Court of the United States decision in Mut. Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013), generic drug manufacturers were given what Justice Sotomayor called “immunity” from state law based design-defect claims when the claims “turn on the adequacy of the drug’s warnings.” In Bartlett, the plaintiff Karen Bartlett was […]